Skip to main content

Table 3 In hospital treatment-related factors during follow-up

From: Risk factors for prolonged hospitalization as a marker for difficult-to-manage exacerbations of chronic obstructive lung disease (COPD): the DiMECO Study

 

Total

Nonprolonged LOS

Prolonged LOS

P

N = 434

n = 197 (45.4)

n = 237(54.6)

 

(%)

   

History of frequent usage of antibiotics, n (%)

n = 430

n = 195

n = 235

0.0021

Yes

176 (40.9)

64 (32.8)

112 (47.4)

 

Antibiotic switch during hospitalization, n (%)

n = 419

n = 192

n = 227

< 0.0011

Yes

78 (18.6)

16 (8.3)

62 (27.3)

 

Antibiotics longer than 7 days, n (%)

n = 421

n = 191

n = 230

< 0.0011

Yes

222 (52.7)

47 (24.6)

175 (76.1)

 

Corticosteroid longer than 7 days, n (%)

n = 429

n = 197

n = 232

< 0.0011

Yes

138 (32.2)

23 (11.7)

115 (49.6)

 

Additional doses of corticosteroids, n (%)

n = 431

n = 197

n = 234

< 0.0011

Yes

88 (20.4)

24 (12.2)

64 (27.4)

 

SABA/SAMA more than 3 days n (%)

n = 432

n = 197

n = 235

< 0.0011

Yes

254 (58.8)

91 (46.2)

163 (69.4)

 

Need for theophylline, n (%)

n = 429

n = 195

n = 234

0.0021

Yes

83 (19.3)

25 (12.8)

58 (24.8)

 

Diuretics, n (%)

n = 430

n = 196

n = 234

0.0021

Yes

120 (27.9)

40 (20.4)

80 (34.2)

 

Increasing O2 requirement at follow-up, n (%)

n = 431

n = 197

n = 234

< 0.0011

Yes

168 (39.0)

44 (22.3)

124 (53.0)

 

In hospital NIVM at follow-up, n (%)

n = 432

n = 197

n = 235

< 0.0011

Yes

145 (33.6)

44 (22.3)

101 (43.0)

 

Increasing pressure of NIVM at follow-up, n (%)

n = 145

n = 44

n = 101

< 0.0011

Yes

72 (49.7)

12 (27.3)

60 (59.4)

 

Nutritional support, n (%)

n = 431

n = 197

n = 234

< 0.0011

Yes

84 (19.5)

16 (8.1)

68 (29.1)

 

Need for physiotherapy, n (%)

n = 432

n = 197

n = 235

< 0.0011

Yes

157 (36.3)

46 (23.4)

111 (47.2)

 

Inability to be discharged due to the delay of the examination, n (%)

n = 431

n = 196

n = 235

< 0.0011

Yes

42 (9.7)

6 (3.1)

36 (15.3)

 
  1. 1Chi-square test
  2. Abbreviations: NIMV: Noninvasive mechanical ventilation, SABA/SAMA: short acting beta2 agonist, short acting muscarinic antagonist